Try our Advanced Search for more refined results

IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION

Track this case

Case Number:

2:16-md-02724

Court:

Pennsylvania Eastern

Nature of Suit:

Other Statutes: Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

CYNTHIA M. RUFE

Firms

Companies

Government Agencies

Sectors & Industries:

  1. March 10, 2026

    Former Conn. Prosecutor Can Stay On Generic-Drug Case

    Connecticut's former assistant attorney general can continue to represent insurers Humana and Molina Healthcare Inc. in multidistrict litigation over alleged price-fixing of generic drugs, after the Pennsylvania federal judge overseeing the case agreed Monday with a report that the attorney has no information that had not already been shared.

  2. March 04, 2026

    Sandoz Parent Targets Walmart, Southwest Generic Drug Suits

    Sandoz parent company Sandoz AG contested generic drug price-fixing complaints from Southwest Airlines, Walmart, Walgreen and United Healthcare, arguing that the direct action plaintiffs cannot pursue the company in the wider Pennsylvania federal court multidistrict litigation because the Swiss firm is too far removed from its Sandoz Inc. subsidiary.

  3. March 04, 2026

    Buyers Finalize $58M Generic-Pricing Deal With 3 Drugmakers

    Purchasers of certain generic drugs asked a Pennsylvania federal court for final approval of settlements worth a total of at least $58 million with Glenmark Pharmaceutical Inc., Greenstone LLC and Pfizer Inc. over claims the companies colluded with others to keep drug prices high.

  4. March 02, 2026

    Epic Must Face Price Conspiracy Claims Over Gallstone Drug

    Epic Pharma LLC must face the majority of suits by hospitals, insurers and other drug purchasers alleging it conspired to raise and control the price of gallstone medication ursodiol, a Pennsylvania federal judge ruled Monday.

  5. February 26, 2026

    $200M Antitrust Deal Can Shield Drugmakers In States' Claims

    Sun Pharmaceutical and Taro Pharmaceuticals can use their $200 million settlement with the "end payors" for generic drugs in an alleged price-fixing scheme as a defense in a similar lawsuit brought by 47 states and territories, the Connecticut federal judge overseeing the case ruled Wednesday.

  6. February 25, 2026

    $17.9M Drug Price-Fixing Deal Advances Despite Objections

    A Connecticut federal judge on Wednesday advanced a $17.9 million generic drug price-fixing settlement between 48 states and territories and pharmaceutical companies Bausch Health US LLC, Bausch Health Americas Inc. and Lannett Co. Inc., sidelining objections by consumers suing separately in a Pennsylvania multidistrict litigation case.

  7. January 30, 2026

    Drug Cos. Want Rethink Of DQ Bid Targeting Ex-Prosecutor  

    More than two dozen pharmaceutical companies accused of fixing generic-drug prices have again asked a Pennsylvania federal judge to disqualify a former Connecticut assistant attorney general now in private practice from representing insurers Humana Inc. and Molina Healthcare Inc. in a sprawling multidistrict litigation proceeding.

  8. January 28, 2026

    Generics Makers Want Hospital Drug Data In Price-Fixing MDL

    A group of 150 hospitals suing generic-drug makers for alleged price fixing in multidistrict litigation should hand over data on their drug purchases, the drugmakers have told a Pennsylvania federal court, arguing they don't sell directly to the hospitals and therefore have no records themselves. 

  9. January 26, 2026

    Generics Makers Fight Cert. In Cholesterol Drug Pricing MDL

    Generic-drug makers sought to defeat a bid to certify proposed classes comprising thousands of pharmacies that indirectly purchased and resold generics at the center of sprawling price-fixing litigation, telling a Pennsylvania federal court Monday that certification would result in an "unmanageable trial."

  10. January 23, 2026

    $200M Sun, Taro Generics Deal Gets Final OK

    A Pennsylvania federal judge granted final approval Friday for a $200 million deal resolving employee benefits plans' claims against Sun Pharmaceutical and Taro Pharmaceuticals in the sprawling price-fixing litigation against generic-drug makers, while again ensuring the claims from dozens of state attorneys general remain untouched by the settlement.